OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?

Zacks compares Omnicell (OMCL) and Hims & Hers (HIMS) for value investors, noting OMCL’s stronger earnings-estimate revision activity and superior valuation metrics. OMCL carries a Zacks Rank #2 (Buy) with a forward P/E of 23.87, PEG of 2.78 and P/B of 1.49 and earns a Value grade of B; HIMS is Zacks Rank #3 (Hold) with a forward P/E of 81.15, PEG of 7.75, P/B of 15.35 and a Value grade of D. The analysis concludes OMCL is the better value pick based on those fundamentals and Zacks’ style-score methodology.

Analysis

Market structure: Omnicell (OMCL) looks like the direct beneficiary if hospitals pursue medication automation and recurring SaaS/device service models — wins: hospitals, integrators, installers; losers: manual pharmacy workflows and high-CAC digital incumbents like HIMS. OMCL’s lower forward P/E (~24) and P/B (1.49) imply pricing power from installed-base renewals; HIMS’ inflated P/B (15x) and PEG (~7.8) signal reliance on continued subscriber growth and marketing spend to justify valuation.

Risk assessment: Near-term (days–weeks) the primary risks are earnings/guidance misses and marketing-cost shocks; medium-term (3–9 months) regulatory moves on telehealth reimbursement or device approvals and hospital capital-cycle slowdowns matter most; long-term (1–3 years) is product adoption and retention economics. Tail risks include new telehealth reimbursement cuts, a major OMCL device failure or cybersecurity breach, or a sudden CAC spike for HIMS >+20% QoQ that destroys unit economics.

Trade implications: Favor a tilt into OMCL over HIMS — OMCL is a long candidate with levers (backlog, recurring revenue) that can re-rate; HIMS is a short/avoid if churn or CAC deteriorates. Use relative trades and options to express view while capping downside: stagger entries ahead of next two earnings windows (2–8 weeks), and size initial exposure conservatively (2–3% portfolio) with contingent adds/removals tied to specific KPI beats/misses.

Contrarian angles: Consensus understates execution risk for OMCL integration programs (adoption often slower than vendor guidance), so upside is not guaranteed; conversely, HIMS could surprise if CAC falls >15% YoY and LTV stabilizes. Historical parallels: 2018–20 digital-health drawdowns show fast-growth consumer health names can rerate violently on churn/gross-margin misses. Unintended consequence: rising rates could compress both multiples but hit HIMS harder given negative free cash flow.

Key Decisions for Investors

• Establish a 2–3% long position in OMCL over 2–4 tranches within the next 2–6 weeks; add another 1–2% if OMCL reports revenue growth >10% YoY or recurring revenue contribution expands by >200 bps sequentially.
• Initiate a 1–2% short position in HIMS (or buy 3–6 month put spread 20–30% OTM) sized to portfolio risk; widen short if HIMS CAC increases >10% QoQ or churn rises >100 bps on next report.
• Implement a pair trade: long OMCL (+2%) and short HIMS (−1%) to capture relative-value re-rating; rebalance after next earnings (approx. 4–8 weeks) based on concrete KPI triggers (OMCL backlog, HIMS LTV/CAC).
• Use options to limit downside: buy OMCL 9–12 month call LEAPS 15–25% OTM (sell nearer-term calls to finance if needed) and buy HIMS 3–6 month put spreads 20–30% OTM to profit from downside while capping premium outlay.
• Rotate 3–5% of portfolio from consumer telehealth names into healthcare automation/equipment names over next 1–3 months; cut further exposure if HIMS or peers miss guidance or if macro hospital capex indicators fall >10% YoY.